Sorafenib and Its Effects on Portal Venous Flow in Cirrhotic Patients
Author Information
Author(s): Coriat Romain, Gouya Hervé, Mir Olivier, Ropert Stanislas, Vignaux Olivier, Chaussade Stanislas, Sogni Philippe, Pol Stanislas, Blanchet Benoit, Legmann Paul, Goldwasser François
Primary Institution: Center for Research on Angiogenesis Inhibitors (CERIA), Hôpital Cochin, AP-HP, Paris, France
Hypothesis
The study aims to determine the effect of sorafenib on portal venous flow and portosystemic collateral circulation in patients receiving sorafenib therapy for advanced hepatocellular carcinoma.
Conclusion
Sorafenib is the first anti-angiogenic therapy to demonstrate a beneficial and reversible decrease of portal venous flow among cirrhotic patients.
Supporting Evidence
- All patients under sorafenib therapy had a decrease in portal venous flow of at least 36%.
- No portal venous flow modification was observed in the control group.
- Patients receiving sorafenib therapy showed a significant reduction in portal venous flow.
Takeaway
This study shows that a medicine called sorafenib can help reduce blood flow in the liver of sick patients, which is a good thing.
Methodology
Seven patients with advanced-stage HCC and portal hypertension were treated with sorafenib, and their portal venous flow was evaluated using magnetic resonance imaging before and after treatment.
Limitations
The small sample size limits the generalizability of the results.
Participant Demographics
Patients were aged 62.8 ± 15.7 years, with a mix of male and female participants, and primarily suffering from chronic hepatitis C and alcohol-related liver disease.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website